Titin Truncating Variants in Dilated Cardiomyopathy – Prevalence and Genotype-Phenotype Correlations

Maria Franaszczyk(Institute of Cardiology), Przemysław Chmielewski(Institute of Cardiology), Grażyna Truszkowska(Institute of Cardiology), Piotr Stawiński(Institute of Physiology and Pathology of Hearing), Ewa Michalak(Institute of Cardiology), Małgorzata Rydzanicz(Medical University of Warsaw), Małgorzata Sobieszczańska‐Małek(Institute of Cardiology), Agnieszka Pollak(Institute of Physiology and Pathology of Hearing), Justyna Szczygieł(Institute of Cardiology), Joanna Kosińska(Medical University of Warsaw), Adam Parulski(Institute of Cardiology), Tomasz Stokłosa(Medical University of Warsaw), Agnieszka Tarnowska(Institute of Cardiology), Marcin M. Machnicki(Medical University of Warsaw), Bogna Foss-Nieradko(Institute of Cardiology), Małgorzata Szperl(Institute of Cardiology), Agnieszka Sioma(Institute of Cardiology), Mariusz Kuśmierczyk(Institute of Cardiology), Jacek Grzybowski(Institute of Cardiology), Tomasz Zieliński(Institute of Cardiology), Rafał Płoski(Medical University of Warsaw), Zofia T. Bilińska(Institute of Cardiology)
PLoS ONE
January 3, 2017
Cited by 91Open Access
Full Text

Abstract

TTN gene truncating variants are common in dilated cardiomyopathy (DCM), although data on their clinical significance is still limited. We sought to examine the frequency of truncating variants in TTN in patients with DCM, including familial DCM (FDCM), and to look for genotype-phenotype correlations. Clinical cardiovascular data, family histories and blood samples were collected from 72 DCM probands, mean age of 34 years, 45.8% FDCM. DNA samples were examined by next generation sequencing (NGS) with a focus on the TTN gene. Truncating mutations were followed up by segregation study among family members. We identified 16 TTN truncating variants (TTN trunc) in 17 probands (23.6% of all cases, 30.3% of FDCM, 17.9% of sporadic DCM). During mean 63 months from diagnosis, there was no difference in adverse cardiac events between probands with and without TTN truncating mutations. Among relatives 29 mutation carriers were identified, nine were definitely affected (31%), eight probably affected (27.6%) one possibly affected (3.4%) and eleven were not affected (37.9%). When relatives with all affected statuses were combined, disease penetrance was still incomplete (62.1%) even after exclusion of unaffected relatives under 40 (82%) and was higher in males versus females. In all mutation carriers, during follow-up, 17.4% had major adverse cardiac events, and prognosis was significantly worse in men than in women. In conclusion, TTN truncating variants were observed in nearly one fourth of young DCM patient population, in vast majority without conduction system disease. Incomplete penetrance suggests possible influence of other genetic and/or environmental factors on the course of cardiotitinopathy. Counseling should take into account sex and incomplete penetrance.


Related Papers

No related papers found

Powered by citation graph analysis